Article info
PDFReviews
Which antibody and which cancer in which paraneoplastic syndromes?
- Correspondence to Dr P Gozzard, Division of Clinical Neurology, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK; p.gozzard{at}nhs.net
Citation
Which antibody and which cancer in which paraneoplastic syndromes?
Publication history
- First published September 21, 2010.
Online issue publication
April 14, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Republished: Which antibody and which cancer in which paraneoplastic syndromes?
- Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition
- Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
- Rhombencephalomyelitis due to possible paraneoplastic syndrome associated with Hodgkin’s lymphoma
- Opsoclonus-myoclonus paraneoplastic syndrome in nasopharyngeal carcinoma
- A rare case of long-term paraesthesia diagnosed as a paraneoplastic syndrome by anti-SOX1 antibody determination
- Recommended diagnostic criteria for paraneoplastic neurological syndromes
- Protein kinase Cγ autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer
- Delayed onset of a second paraneoplastic neurological syndrome in eight patients
- Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy